America Can’t Lower Healthcare Costs Without A Moonshot

Why It Matters

A systemic overhaul is essential to stop health‑care spending from outpacing wages and to protect the nation’s economic competitiveness.

Key Takeaways

• U.S. healthcare spending exceeds $5.6 trillion, 19% of GDP.
• Fee‑for‑service drives volume, inflating costs and limiting price transparency.
• Pay‑for‑value fails until ~63% of revenue is capitated.
• Drug list prices average $370,000 annually, double foreign equivalents.
• Potential $1 trillion savings could trigger a healthcare moonshot.

Pulse Analysis

The United States now spends more than $5.6 trillion on health care—about 19 % of GDP and roughly double the per‑capita outlays of other advanced economies. Premiums for a family plan hover near $27,000, with workers shouldering about $7,000 out of pocket, forcing employers to choose between wages and benefits. Incremental tactics such as prior authorizations or high‑deductible plans have trimmed the edges but have not addressed the underlying payment architecture. Without a systemic shock, the affordability gap will keep widening, pressuring both the labor market and public budgets.

The fee‑for‑service model rewards every test, visit and procedure, creating a perverse incentive to do more rather than better. Over 90 % of private claims still follow this volume‑based logic, while hospital consolidations leave one or two systems dominating many metros, eroding competition. Pharmaceutical firms exploit patent extensions and limited government price negotiation, pushing median list prices above $370,000—twice what peers pay abroad. Breaking this cycle would require either robust antitrust enforcement or direct price caps, both politically fraught moves that have so far been deemed too risky for legislators.

Pay‑for‑value promises lower costs by rewarding outcomes, yet real‑world data show clinicians only shift behavior when roughly 63 % of revenue comes from capitated contracts. Insurers often retain the fixed payment and continue to reimburse providers fee‑for‑service, diluting the incentive. If capitation becomes more lucrative, insurers and venture‑backed health platforms could pour capital into data infrastructure and integrated care networks, unlocking the estimated $1 trillion in chronic‑disease savings cited by the CDC. Such a financial upside—or a voter‑driven backlash against unaffordable premiums—could provide the fear or reward catalyst needed for a true healthcare moonshot.